Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial
American Journal of Transplantation , Volume 12 - Issue 11 p. 3008- 3020
In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in 2.9% of EVR+Reduced TAC patients versus 7.0% of TAC Controls (p = 0.035). The change in adjusted estimated GFR from randomization to month 12 was superior with EVR+Reduced TAC versus TAC Control (difference 8.50 mL/min/1.73 m2, 97.5% CI 3.74, 13.27 mL/min/1.73 m2, p<0.001 for superiority). Drug discontinuation for adverse events occurred in 25.7% of EVR+Reduced TAC and 14.1% of TAC Controls (relative risk 1.82, 95% CI 1.25, 2.66). Relative risk of serious infections between the EVR+Reduced TAC group versus TAC Controls was 1.76 (95% CI 1.03, 3.00). Everolimus facilitates early tacrolimus minimization with comparable efficacy and superior renal function, compared to a standard tacrolimus exposure regimen 12 months after liver transplantation.
|Efficacy, everolimus, liver transplantation, reduced, tacrolimus, withdrawal|
|American Journal of Transplantation|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
de Simone, P, Nevens, F, de Carlis, L, Metselaar, H.J, Beckebaum, S, Saliba, F, … Jung, G. (2012). Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. American Journal of Transplantation, 12(11), 3008–3020. doi:10.1111/j.1600-6143.2012.04212.x